- document
-
Gart, E. (author), van Duyvenvoorde, W. (author), Snabel, J. (author), de Ruiter, C. (author), Attema, J. (author), Caspers, M.P.M. (author), Lek, S. (author), van Heuven, B.J. (author), Speksnijder, A.G.C.L. (author), Giera, M. (author), Menke, A. (author), Salic, K. (author), Bence, K.K. (author), Tesz, G.J. (author), Keijzer, J. (author), Kleemann, R. (author), Morrison, M.C. (author)Background: NAFLD progression, from steatosis to inflammation and fibrosis, results from an interplay of intra- and extrahepatic mechanisms. Disease drivers likely include signals from white adipose tissue (WAT) and gut. However, the temporal dynamics of disease development remain poorly understood. Methods: High-fat-diet (HFD)-fed Ldlr-/-...article 2023
- document
-
Seidel, F. (author), Kleemann, R. (author), van Duyvenvoorde, W. (author), van Trigt, N. (author), Keijzer, N. (author), van der Kooij, S. (author), van Kooten, C. (author), Verschuren, L. (author), Menke, A. (author), Kiliaan, A.J. (author), Winter, J. (author), Hughes, T.R. (author), Morgan, P. (author), Baas, F. (author), Fluiter, K. (author), Morrison, M.C. (author)Background: Chronic inflammation is an important driver in the progression of non-alcoholic steatohepatitis (NASH) and atherosclerosis. The complement system, one of the first lines of defense in innate immunity, has been implicated in both diseases. However, the potential therapeutic value of complement inhibition in the ongoing disease remains...article 2022
- document
-
Gart, E. (author), van Duyvenvoorde, W. (author), Caspers, M.P.M. (author), van Trigt, N. (author), Snabel, J. (author), Menke, A. (author), Keijer, J. (author), Salic, K. (author), Morrison, M.C. (author), Kleemann, R. (author)Non-alcoholic steatohepatitis (NASH) is associated with a disturbed metabolism in liver, insulin resistance, and excessive accumulation of ectopic fat. Branched-chain amino acids (BCAAs) may beneficially modulate hepatic lipids, however, it remains unclear whether individual BCAAs can attenuate already established NASH and associated oxidative...article 2022
- document
-
Morrison, M.C. (author), Gart, E. (author), van Duyvenvoorde, W. (author), Snabel, J. (author), Nielsen, M.J. (author), Leeming, D.J. (author), Menke, A. (author), Kleemann, R. (author)The development of non-alcoholic steatohepatitis (NASH) has been associated with alterations in gut microbiota composition and reduced gut barrier function. Akkermansia muciniphila is a gut microbe that is thought to have health-promoting properties, including the ability to improve gut barrier function and host metabolism, both when...article 2022
- document
-
Mueller, A.M. (author), Kleemann, R. (author), Gart, E. (author), van Duyvenvoorde, W. (author), Verschuren, L. (author), Caspers, M. (author), Menke, A. (author), Krömmelbein, N. (author), Salic, K. (author), Burmeister, Y. (author), Seilheimer, B. (author), Morrison, M.C. (author)Background: Non-alcoholic fatty liver disease (NAFLD) is a complex multifactorial disorder that is characterised by dysfunctional lipid metabolism and cholesterol homeostasis, and a related chronic inflammatory response. NAFLD has become the most common cause of chronic liver disease in many countries, and its prevalence continues to rise in...article 2021
- document
-
Gart, E. (author), van Duyvenvoorde, W. (author), Toet, K. (author), Caspers, M.P.M. (author), Verschuren, L. (author), Nielsen, M.J. (author), Leeming, D.J. (author), Lima, E.S. (author), Menke, A. (author), Hanemaaijer, R. (author), Keijer, J. (author), Salic, K. (author), Kleemann, R. (author), Morrison, M.C. (author)In obesity-associated non-alcoholic steatohepatitis (NASH), persistent hepatocellular damage and inflammation are key drivers of fibrosis, which is the main determinant of NASH-associated mortality. The short-chain fatty acid butyrate can exert metabolic improvements and anti-inflammatory activities in NASH. However, its effects on NASH...article 2021
- document
-
Morrison, M.C. (author), Verschuren, L. (author), Salic, K. (author), Verhij, J. (author), Menke, A. (author), Wielinga, P.Y. (author), Iruarrizaga-Lejarretts, M. (author), Gole, L. (author), Yu, W.M. (author), Turner, S. (author), Caspers, M.P.M. (author), Martinez-Arranz, I. (author), Pieterman, E. (author), Stoop, R. (author), van Koppen, A. (author), van den Hoek, A.M. (author), Mato, J.M. (author), Hanemaaijer, R. (author), Alonso, C. (author), Kleemann, R. (author)Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventions in the process of NASH/fibrosis. We investigated the representation of molecular disease...article 2018
- document
-
Morrison, M.C. (author), Mulder, P. (author), Salic, K. (author), Verheij, J. (author), Liang, W. (author), van Duyvenvoorde, W. (author), Menke, A. (author), Kooistra, T. (author), Kleemann, R. (author), Wielinga, P.Y. (author)Background/objectives: Non-alcoholic steatohepatitis (NASH) is a serious liver condition, closely associated with obesity and insulin resistance. Recent studies have suggested an important role for inflammasome/caspase-1 in the development of NASH, but the potential therapeutic value of caspase-1 inhibition remains unclear. Therefore, we aimed...article 2016
- document
-
Keatinge, M. (author), Bui, H. (author), Menke, A. (author), Chen, Y.C. (author), Sokol, A.M. (author), Bai, Q. (author), Ellett, F. (author), da Costa, M. (author), Burke, D. (author), Gegg, M. (author), Trollope, L. (author), Payne, T. (author), McTighe, A. (author), Mortiboys, H. (author), de Jager, S. (author), Nuthall, H. (author), Kuo, M.S. (author), Fleming, A. (author), Schapira, A.H.V. (author), Renshaw, S.A. (author), Highley, J.R. (author), Chacinska, A. (author), Panula, P. (author), Burton, E.A. (author), O'Neill, M.J. (author), Bandmann, O. (author)Autosomal recessively inherited glucocerebrosidase 1 (GBA1) mutations cause the lysosomal storage disorder Gaucher's disease (GD). Heterozygous GBA1 mutations (GBA1+/-) are the most common risk factor for Parkinson's disease (PD). Previous studies typically focused on the interaction between the reduction of glucocerebrosidase (enzymatic)...article 2015
- document
-
Mesens, N. (author), Crawfordb, A.D. (author), Menke, A. (author), Hung, P.D. (author), van Goethem, F. (author), Nuyts, R. (author), Hansen, E. (author), Wolterbeek, A. (author), van Gompel, J. (author), de Witte, P. (author), Esguerra, C.V. (author)Drug-induced liver injury (DILI) is poorly predicted by single-cell-based assays, probably because of the lack of physiological interactions with other cells within the liver. An intact whole liver system such as one present in zebrafish larvae could provide added value in a screening strategy for DILI; however, the possible occurrence of other...article 2015
- document
-
Beker van Woudenberg, A. (author), Snel, C. (author), Rijkmans, E. (author), de Groot, D. (author), Bouma, M. (author), Hermsen, S. (author), Piersma, A. (author), Menke, A. (author), Wolterbeek, A. (author)To improve the predictability of the zebrafish embryotoxicity test (ZET) for developmental (neuro)toxicity screening, we used a multiple-endpoints strategy, including morphology, motor activity (MA), histopathology and kinetics. The model compounds used were antiepileptic drugs (AEDs): valproic acid (VPA), carbamazepine (CBZ), ethosuximide (ETH)...article 2014
- document
-
Beker van Woudenberg, A. (author), Wolterbeek, A. (author), te Brake, L. (author), Snel, C. (author), Menke, A. (author), Rubingh, C. (author), de Groot, D. (author), Kroese, D. (author)Zebrafish embryos were exposed to different organotin compounds during very early development (<100. h post fertilization). Morphology, histopathology and swimming activity (in a motor activity test) were the endpoints analyzed. DBTC was, by far, the most embryotoxic compound at all time points and endpoints studied. In fact, we observed a clear...article 2013
- document
-
Menke, A. (author), Wolterbeek, A. (author), Snel, C. (author), Bruijntjes, J. (author), Groot, D.D. (author), Oostrum, L.V. (author), Waalkens, I. (author), Kuper, C.F. (author)Characteristic susceptibility to environmental and pharmaceutical exposure may occur during periods in life of marked histophysiological changes of the immune system. Perinatal development is such a period; pregnancy followed by lactation is potentially another one. Here, we explored the influence of pregnancy and lactation on the model...article 2012